Heterologous expression of carcinoembryonic antigen in Lactococcus lactis via LcsB-mediated surface displaying system for oral vaccine development

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 6, 2016, Pages 851-858

  Zhang, Xiaowei ^a   Hu, Shumin ^b,c   Du, Xue ^a   Li, Tiejun ^a   Han, Lanlan ^c   Kong, Jian ^c  

^a Health Service Center of Science and Technology Exchange   (China)

^b TSINGTAO BREWERY CO LTD   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

carcinoembryonic antigen; gene expression; Lactococcus lactis; S layer

Indexed keywords

BACTERIAL VECTOR; CARCINOEMBRYONIC ANTIGEN; CHLORAMPHENICOL; IMMUNOGLOBULIN A; NISIN; SECRETORY IMMUNOGLOBULIN; CANCER VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; HETEROLOGOUS EXPRESSION; IMMUNE RESPONSE; LACTIC ACID BACTERIUM; LACTOBACILLUS CRISPATUS; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROMOTER REGION; SHUTTLE VECTOR; SPLEEN; VACCINATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

ANIMALS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; ESCHERICHIA COLI; GENETIC VECTORS; IMMUNOGLOBULIN A; IMMUNOTHERAPY; LACTOCOCCUS LACTIS; MICE; MICE, INBRED BALB C; NEOPLASMS; VACCINATION;

EID: 84921982477     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2014.11.009     Document Type: Article

References (29)

1. 1 Benchimol, S., Fuks, A., Jothy, S., Beauchemin, N., Shirota, K., Stanners, C.P., Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57 (1989), 327–334.
2. 2 Ojima, T., Iwahashi, M., Nakamura, M., Matsuda, K., Nakamori, M., Ueda, K., et al. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Int J Cancer 120 (2007), 585–593.
3. 3 Greiner, J.W., Zeytin, H., Anver, M.R., Schlom, J., Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 62 (2002), 6944–6951.
4. 4 Bernstein, M.B., Chakraborty, M., Wansley, E.K., Guo, Z., Franzusoff, A., Mostböck, S., et al. Recombinant Saccharomyces cerevisiae (yeast-CEA) as a potent activator of murine dendritic cells. Vaccine 26 (2008), 509–521.
5. 5 Cawood, R., Hills, T., Wong, S.L., Alamoudi, A.A., Beadle, S., Fisher, K.D., et al. Recombinant viral vaccines for cancer. Trends Mol Med 18 (2012), 564–574.
6. 6 Li, D., Hua, S., Fan, Y., Xu, S., Duan, X., Liu, L., et al. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice. Immunol Lett 135 (2011), 124–128.
7. 7 Marshall, J., Carcinoembryonic antigen-based vaccines. Semin Oncol 30 (2003), 30–36.
8. 8 McAneny, D., Ryan, C.A., Beazley, R.M., Kaufman, H.L., Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Ann Surg Oncol 3 (1996), 495–500.
9. 9 Goverdhan, R., Polymeric delivery systems in biotechnology. Ashwin, A.R., Praveen, K.G., Anant, R., (eds.) Current topics in biotechnology, 2008, Biotechnology Society, Bareilly, 14–19.
10. 10 Hellgren, I., Gorman, J., Sylvén, C., Factors controlling the efficiency of Tat-mediated plasmid DNA transfer. J Drug Target 12 (2004), 39–47.
11. 11 Berlec, A., Ravnikar, M., Štrukelj, B., Lactic acid bacteria as oral delivery systems for biomolecules. Die Pharmazie 67 (2012), 891–898.
12. 12 Tarahomjoo, S., Development of vaccine delivery vehicles based on lactic acid bacteria. Mol Biotechnol 51 (2012), 183–199.
13. 13 Bolotin, A., Wincker, P., Mauger, S., Jaillon, O., Malarme, K., Weissenbach, J., et al. The complete genome sequence of the lactic acid bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res 11 (2001), 731–753.
14. 14 Kimoto, H., Nomura, M., Kobayashi, M., Mizumachi, K., Okamoto, T., Survival of lactococci during passage through mouse digestive tract. Can J Microbiol 49 (2003), 707–711.
15. 15 Klijn, N., Weerkamp, A.H., De Vos, W.M., Genetic marking of Lactococcus lactis shows its survival in the human gastrointestinal tract. Appl Environ Microbiol 61 (1995), 2771–2774.
16. 16 Lei, H., Sheng, Z., Ding, Q., Chen, J., Wei, X., Lam, D.M.K., et al. Evaluation of oral immunization with recombinant avian influenza virus HA1 displayed on the Lactococcus lactis surface and combined with the mucosal adjuvant cholera toxin subunit B. Clin Vaccine Immunol 18 (2011), 1046–1051.
17. 17 Wang, K., Huang, L., Kong, J., Zhang, X., Expression of the capsid protein of porcine circovirus type 2 in Lactococcus lactis for oral vaccination. J Virol Methods 150 (2008), 1–6.
18. 18 Mierau, I., Kleerebezem, M., 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68 (2005), 705–717.
19. 19 Ribeiro, L.A., Azevedo, V., Le Loir, Y., Oliveira, S.C., Dieye, Y., Piard, J.C., et al. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Microbiol 68 (2002), 910–916.
20. 20 Wells, J.M., Wilson, P.W., Norton, P.M., Gasson, M.J., Le Page, R.W., Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol Microbiol 8 (1993), 1155–1162.
21. 21 Nouaille, S., Ribeiro, L.A., Miyoshi, A., Pontes, D., Le Loir, Y., Oliveira, S.C., et al. Heterologous protein production and delivery systems for Lactococcus lactis. Genet Mol Res 2 (2003), 102–111.
22. 22 Hu, S., Kong, J., Kong, W., Guo, T., Ji, M., Characterization of a novel LysM domain from Lactobacillus fermentum bacteriophage endolysin and its use as an anchor to display heterologous proteins on the surfaces of lactic acid bacteria. Appl Environ Microbiol 76 (2010), 2410–2428.
23. 23 Hu, S., Kong, J., Sun, Z., Han, L., Kong, W., Yang, P., Heterologous protein display on the cell surface of lactic acid bacteria mediated by the S-layer protein. Microb Cell Fact 10 (2011), 86–98.
24. 24 Leenhouts, K., Buist, G., Kok, J., Anchoring of proteins to lactic acid bacteria. Antonie Van Leeuwenhoek 76 (1999), 367–376.
25. 25 Holo, H., Nes, I.F., High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. Appl Environ Microbiol 55 (1989), 3119–3123.
26. 26 Sun, Z., Kong, J., Hu, S., Kong, W., Lu, W., Liu, W., Characterization of a S-layer protein from Lactobacillus crispatus K313 and the domains responsible for binding to cell wall and adherence to collagen. Appl Microbiol Biotechnol 97 (2013), 1941–1952.
27. 27 Challacombe, S.J., Rahman, D., Jeffery, H., Davis, S.S., O'Hagan, D.T., Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology 76 (1992), 164–168.
28. 28 Norton, P.M., Brown, H.W., Le Page, R.W., The immune response to Lactococcus lactis: implications for its use as a vaccine delivery vehicle. FEMS Microbiol Lett 120 (1994), 249–256.
29. 29 Wells, J.M., Mercenier, A., Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 6 (2008), 349–362.